Abstract 1449P
Background
KN046 is a novel bispecific domain antibody, which blocks both PD-L1 and CTLA-4. KN046 combined with platinum-based chemotherapy as 1L treatment for NSCLC had shown promising efficacy and tolerability in the previous clinical trial. (2022 ESMO 1029P). Herein, we present the promising preliminary data of KN046 combination with axitinib as 1L treatment for NSCLC.
Methods
Eligible subjects with recurrent/metastatic NSCLC, treatment-naive and PD-L1 expression ≥1% will be enrolled and receive KN046 5mg/kg IV Q3W and axitinib 5mg orally bid. This study adopts a Simon’s optimal two-stage design. In the 1st stage, 17 subjects will be enrolled, and the 2nd stage enrollment will be discontinued if objective response (CR or PR) observed in less than 5 subjects. Otherwise, 37 subjects will be enrolled in the 2nd stage. The primary endpoint is ORR. The secondary endpoints include DoR, safety, PFS and OS.
Results
As of data cut-off date (Mar 17, 2023), 22 subjects were enrolled, the median age was 64.5y (min:37, max:73), 90.9% were male. ECOG score was 0 (4.5%) and 1 (95.5%). PD-L1 expression was ≥50% in 22.7% of the subjects. 15 subjects completed at least one tumor assessment. In the efficacy analysis set, the ORR was 66.7% (10/15). The median follow-up for DoR was 4.21 m (95% CI,1.22, NE). The 3-m DoR rate was 100% (95% CI, 100.00, 100.00). The median study follow-up was 2.83 m (95% CI,0.72, 5.12). The 6-m PFS rate was 76.6 % (95% CI, 41.16, 92.28), The mPFS and mOS was not reached. The incidence of TEAE was 81.8% (18/22), of which KN046-related TRAE was 63.6% (14/22). Majority was grade 1-2. The incidence of KN046-related CTCAE Grade ≥3 TRAE was 9.1% (2/22). The most frequent TRAE was AST increased 9.1% (2/22) and ALT increased 4.5% (1/22). The incidence of irAE was 13.6% (3/22), No CTCAE Grade ≥3 irAE was found. There was no KN046-related death.
Conclusions
KN046 combined with axitinib is well tolerated and has shown very promising efficacy and safety signal in 1L treatment for advanced NSCLC. The 2nd stage of enrollment is ongoing and a phase 3 RCT is planned to further confirm the clinical benefit of KN046 and axitinb combo as a viable chemo free option for the 1st line NSCLC patient.
Clinical trial identification
NCT05420220.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Jiangsu Alphamab Biopharmaceuticals Co.,Ltd., Suzhou, China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1453P - Trends in treatment regimens and survival in the use of immune checkpoint inhibitors for lung cancer treatment in the Netherlands from 2016-2020
Presenter: Erick Suazo Zepeda
Session: Poster session 20
1454P - Radiomic analysis predicts response to immunotherapy in metastastic non-small cell lung cancer (mNSCLC): Preliminary results
Presenter: Salvatore Grisanti
Session: Poster session 20
1455P - Nivolumab (nivo) resumption in patients with advanced or metastatic non-small cell lung cancer (aNSCLC): Survival outcomes based on France and Germany real-world data (RWD)
Presenter: Maurice Pérol
Session: Poster session 20
1456P - Exploring biological and molecular factors as outcome predictors for pembrolizumab (Pem) or pembrolizumab-chemotherapy (Pem-CT) in advanced non-small cell lung cancer (NSCLC)
Presenter: Lodovica Zullo
Session: Poster session 20
1457P - Oligometastatic non-small cell lung cancer: Impact of local and systemic treatment approaches on clinical outcome
Presenter: Marcel Wiesweg
Session: Poster session 20
1459P - Preliminary efficacy and safety of KN046 (a bispecific anti-PD-L1/CTLA-4) in patients with metastatic non-small cell lung cancer who previously treated with immune checkpoint inhibitor(s)
Presenter: Caicun Zhou
Session: Poster session 20
1460P - GALLANT-1: GB1211 galectin-3 (Gal-3) inhibitor plus atezolizumab (atz) for first line treatment in patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC)
Presenter: Francisco Aparisi Aparisi
Session: Poster session 20
1461P - Predictive value of residual FDG-PET metabolic activity in metastatic non-small cell lung cancer (mNSCLC) patients (pts) with long-lasting response to immune checkpoint inhibitors (ICIs)
Presenter: Toublanc Anne-Claire
Session: Poster session 20
1463P - IL-6 triggers chemoimmunotherapy resistance by creating immunosuppressive tumor microenvironment in non-small cell lung cancer
Presenter: Yaning Yang
Session: Poster session 20